Terms ending in 2031
Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,452,222 | Nucleic Acids Encoding Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 10,253,083 | Therapeutic Uses of Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 10,702,588 | Modified Relaxin Polypeptides Comprising A Non-Naturally Encoded Amino Acid In The A Chain In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 10,751,391 | Methods of Treatment Using Modified Relaxin Polypeptides Comprising a Non-Naturally Encoded Amino Acid In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 11,786,578 | Modified Relaxin Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 9,567,386 | Therapeutic Uses of Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.